Selecta biosciences, inc (SELB)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

-62,896

-55,350

-55,113

-59,120

-61,522

-65,336

-70,229

-68,904

-66,075

-65,321

-59,860

-52,912

-43,868

-36,210

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

719

700

700

800

981

1,000

1,033

1,014

825

800

822

822

797

800

0

0

0

Amortization of premiums (accretion of discounts) on investments

107

154

154

141

116

101

68

18

-112

-233

-280

-353

-282

-193

0

0

0

Non-cash lease expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal of property and equipment

-35

-104

-71

59

11

81

0

0

0

-

-

-

-

-

-

-

-

Stock‑based compensation expense

5,390

5,161

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Allocated Share-based Compensation Expense

-

-

-

-

-

-

-

-

4,541

-

3,642

2,960

2,462

2,051

0

0

0

Non‑cash interest expense

336

402

433

451

461

449

495

451

423

390

336

359

366

263

0

0

0

Fair Value Adjustment of Warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

12

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

0

-

-

-

0

-

-

-

-11

-152

-484

-1,962

-1,567

-610

0

0

0

Prepaid expenses, deposits and other assets

-9,276

-3,179

-4,263

-388

9,206

2,631

1,908

238

-1,958

-1,225

-1,154

-1,062

1,112

831

0

0

0

Restricted cash and other deposits

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts payable

643

-600

231

692

-1,103

-516

-297

82

442

-2,327

322

770

521

2,686

0

0

0

Deferred revenue

339

337

-924

-24

-103

-101

0

0

0

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

10,080

-

0

0

0

Accrued expenses and other liabilities

392

-2,397

-6,345

-4,931

-1,555

2,467

3,648

1,181

4,641

5,650

5,247

6,225

2,710

716

0

0

0

Net cash used in operating activities

-42,893

-51,435

-51,307

-56,216

-65,992

-59,161

-59,074

-58,478

-50,119

-52,026

-37,883

-27,914

-24,907

-19,757

0

0

0

Cash flows from investing activities
Receipts from the maturity of short-term investments

-

-

-

-

-

41,655

60,698

66,966

75,203

60,158

0

0

0

-

-

-

-

Purchases of short-term investments

0

18,188

18,188

19,886

19,878

15,598

28,389

42,905

58,961

61,527

53,834

60,938

41,478

28,416

0

0

0

Sale of short term investments

0

1,992

1,992

1,992

1,992

0

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

182

47

378

433

692

884

665

730

867

733

692

843

501

586

0

0

0

Proceeds from the sale of property and equipment

45

122

88

145

176

99

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

16,213

229

-136

-5,632

8,208

25,272

31,753

23,366

15,379

-2,098

-13,409

-31,248

-35,077

-22,100

0

0

0

Cash flows from financing activities
Repayments of principal on outstanding debt

0

-

-

-

0

-

-

-

-

12,934

12,934

1,836

728

0

0

0

0

Deferred IPO costs paid

-

-

-

-

-

-

-

-

-

-

-

-

-

4,103

0

0

0

Net proceeds from issuance of common stock

0

30,942

30,942

30,942

30,942

0

0

0

0

-

-

-

-

-

-

-

-

Issuance costs paid for December 2019 financing

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Other financing fees

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

8

150

230

335

646

501

507

513

270

706

721

605

578

149

0

0

0

Proceeds from issuance of common stock under Employee Stock Purchase Plan

122

28

28

165

165

196

196

231

231

180

0

0

0

-

-

-

-

Net cash (used in) provided by financing activities

68,564

105,041

36,587

31,814

31,753

697

5,655

12,731

66,366

66,023

63,777

58,805

69,044

67,659

0

0

0

Effect of exchange rate changes on cash

-72

34

-16

-53

-150

-153

-115

-73

-27

78

0

0

0

-

-

-

-

Net change in cash, cash equivalents, and restricted cash

41,812

53,869

-14,872

-30,087

-26,181

-33,345

-21,781

-22,454

31,599

11,977

0

0

0

-

-

-

-

Effect of exchange rate changes on cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Supplement cash flow information
Cash paid for interest

1,143

1,223

1,953

1,229

1,185

1,134

0

0

0

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

0

970

-

0

0

0

Noncash investing and financing activities
Purchase of property and equipment not yet paid

10

0

-165

-38

3

145

405

274

120

103

124

159

272

147

0

0

0

Equity offering costs in accrued liabilities

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

Unrealized gain on marketable securities

-2

0

0

4

15

16

5

10

8

20

-21

-11

-21

-36

0

0

0

Temporary Equity, Accretion to Redemption Value

-

-

-

-

-

-

-

-

-

-

-

-

-

4,566

0

0

0

At-The-Market Offering
Net proceeds from issuance of common stock

2,100

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-